Impact of evidence-based medicine on the treatment of patients with unresectable hepatocellular carcinoma

Alimentary Pharmacology and Therapeutics

Volumn 31, Issue 4, 2010, Pages 493-501

  Giannini, E G ^a   Bodini, G ^a   Corbo, M ^a   Savarino, V ^a   Risso, D ^b   Di Nolfo, M A ^c   Del Poggio, P ^d   BenvegnU L ^e   Farinati, F ^e   Zoli, M ^f   Borzio, F ^g   Caturelli, E ^h   Chiaramonte, M ⁱ   Trevisani, F ^f  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c BOLOGNINI HOSPITAL   (Italy)

^d TREVIGLIO HOSPITAL   (Italy)

^e UNIVERSITY OF PADOVA   (Italy)

^f UNIVERSITY OF BOLOGNA   (Italy)

^g FATEBENEFRATELLI HOSPITAL   (Italy)

^h BELCOLLE HOSPITAL   (Italy)

ⁱ UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; EPIRUBICIN; IODINATED POPPYSEED OIL; MITOXANTRONE; TAMOXIFEN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG EFFICACY; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

AGED; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; ITALY; KAPLAN-MEIERS ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 74049091234     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2009.04198.x     Document Type: Article

References (23)

1. Bosch FX, Ribes J, Clèries M, Diaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2005 9 : 191 211.
2. Benvegnù L, Gios M, Boccato S, et al. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 2004 53 : 744 749.
3. Sangiovanni A, Prati GM, Fasani P, et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology 2006 43 : 1303 1310.
4. Trevisani F, De Notariis S, Rapaccini G, et al. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol 2002 97 : 734 744.
5. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005 42 : 1208 1236.
6. Sherman S. Surveillance for hepatocellular carcinoma and early diagnosis. Clin Liver Dis 2007 11 : 817 837.
7. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008 48 (Suppl. 1 S20 37.
8. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004 127 : S179 88.
9. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002 35 : 1164 1171.
10. Llovet JM, Real MI, Montaña X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised study. Lancet 2002 359 : 1734 1739.
11. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003 37 : 429 442.
12. Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Brit J Surg 1973 60 : 646 649.
13. Commissione "Epatocarcinoma" Dell'Associazione Italiana per lo Studio del Fegato. Epatocarcinoma: Linee Guida per la Diagnosi e la Terapia. Bologna : Tipografia Moderna, 1998 : 235 268.
14. Bruix J EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001 35 : 421 430.
15. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996 334 : 693 699.
16. The Cancer of the Liver Italian Program (CLIP) Investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 1998 28 : 751 755.
17. Giannini EG, Risso D, Testa R, et al. Prevalence and prognostic significance of the presence of esophageal varices in patients with hepatocellular carcinoma. Clin Gastroenterol Hepatol 2006 4 : 1378 1384.
18. Nowak AK, Stockler MR, Chow PK, et al. Use of tamoxifen in advanced-stage hepatocellular carcinoma. A systematic review Cancer 2005 103 : 1408 1414.
19. Grilli R, Apolone G, Marsoni S, Nicolucci A, Zola P, Liberati A. The impact of patients management guidelines on the care of breast, colorectal, and ovarian cancer patients in Italy. Med Care 1991 29 : 50 63.
20. Lomas J, Anderson GM, Domnick-Pierre K, et al. Do practice guidelines guide practice? The effect of a consensus statement on the practice of physicians. N Engl J Med 1989 321 : 1306 1311.
21. Cabana MD, Rand CS, Powe NR, et al. Why don't physcians follow clinical practice guidelines? A framework for improvement. JAMA 1999 282 : 1458 1465.
22. Cruz-Correa M, Gross CP, Canto MI, et al. The impact of practice guidelines in the management of Barrett esophagus: a national prospective cohort study of physicians. Arch Intern Med 2001 161 : 2588 2595.
23. Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007 30 : 6 25.